Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144494 · ClinicalTrials.gov registry record · Early Phase 1
Aqueous Humor Dynamics and Brimonidine
A Early Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 35
- Enrollment target
NCT01144494 is a Early Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 35 participants.
The verdict
NCT01144494, a Early Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This single-center, investigator-masked, crossover study is designed to investigate the circadian rhythms of aqueous humor dynamics in human subjects with ocular hypertension (OHT) before and after intervention with a commonly used ocular hypotensive medication, brimonidine for six weeks.
Interventions
- DRUG Artificial tears
- DRUG Brimonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-08-01 |
| Est. Completion | 2011-10-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144494
The ClinicalTrials.gov registry entry for NCT01144494 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Artificial tears is the first listed.
NCT01144494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144494 about?
NCT01144494 is a clinical study titled "Aqueous Humor Dynamics and Brimonidine". This single-center, investigator-masked, crossover study is designed to investigate the circadian rhythms of aqueous humor dynamics in human subjects with ocular hypertension (OHT) before and after intervention with a commonly used ocular hypotensive medication, brimonidine for six weeks.
What is the current status of trial NCT01144494?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2010-08-01. Estimated completion is 2011-10-01.
What interventions are being tested in trial NCT01144494?
The interventions under investigation include: Artificial tears (DRUG), Brimonidine (DRUG).
Who is sponsoring clinical trial NCT01144494?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.